Trials / Withdrawn
WithdrawnNCT02988297
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Revalesio Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RNS60 | Nebulized RNS60 will be administered by daily inhalation for 24 weeks. |
| DRUG | Placebo | Nebulized Placebo will be administered by daily inhalation for 24 weeks. |
Timeline
- Start date
- 2026-10-01
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
- First posted
- 2016-12-09
- Last updated
- 2026-04-16
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02988297. Inclusion in this directory is not an endorsement.